Real-world multiple myeloma management practice patterns and outcomes in selected Central and Eastern European countries

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10382753" target="_blank" >RIV/00216208:11110/18:10382753 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/18:10382753

Výsledek na webu

<a href="https://doi.org/10.20452/pamw.4305" target="_blank" >https://doi.org/10.20452/pamw.4305</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.20452/pamw.4305" target="_blank" >10.20452/pamw.4305</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Real-world multiple myeloma management practice patterns and outcomes in selected Central and Eastern European countries

Popis výsledku v původním jazyce

INTRODUCTION: Multiple myeloma (MM) treatment has evolved substantially in recent years. Solid data on the impact of treatment strategies on patient outcomes beyond clinical trials are scarce, especially in budget-restricted environments with limited access to new treatments. OBJECTIVES: This study investigated treatment practices, patterns, and outcomes in real-world clinical practice in Bulgaria, Croatia, Czech Republic, Poland, Romania, and Slovakia. PATIENTS AND METHODS: This was a noninterventional, observational chart review comprising a cross-sectional and a retrospective longitudinal phase observing adult patients with symptomatic MM at all stages of therapy. RESULTS: The study revealed structural differences in clinical practice compared with a similarly designed study previously conducted in 7 Western European countries. Stem cell transplantation was performed in less than half of newly diagnosed eligible patients. The most frequently used first-line regimens were bortezomib based, with frequent bortezomib retreatment after the first relapse. Lenalidomide-based regimens were predominant in the third and subsequent lines of therapy. Depth of response decreased with each treatment line, with half of patients achieving at least very good partial response (&gt;= VGPR) in the first line, while only one-fourth achieved &gt;= VGPR in the third or subsequent lines. Time to progression was longer in patients with better response levels. CONCLUSIONS: Inadequate access to advanced antimyeloma regimens and-in some countries-stem cell transplantation highlights the challenges of MM treatment in the region. Information on real-world patient management and its outcomes can provide valuable input for decision makers to effectively allocate limited resources.

Název v anglickém jazyce

Real-world multiple myeloma management practice patterns and outcomes in selected Central and Eastern European countries

Popis výsledku anglicky

INTRODUCTION: Multiple myeloma (MM) treatment has evolved substantially in recent years. Solid data on the impact of treatment strategies on patient outcomes beyond clinical trials are scarce, especially in budget-restricted environments with limited access to new treatments. OBJECTIVES: This study investigated treatment practices, patterns, and outcomes in real-world clinical practice in Bulgaria, Croatia, Czech Republic, Poland, Romania, and Slovakia. PATIENTS AND METHODS: This was a noninterventional, observational chart review comprising a cross-sectional and a retrospective longitudinal phase observing adult patients with symptomatic MM at all stages of therapy. RESULTS: The study revealed structural differences in clinical practice compared with a similarly designed study previously conducted in 7 Western European countries. Stem cell transplantation was performed in less than half of newly diagnosed eligible patients. The most frequently used first-line regimens were bortezomib based, with frequent bortezomib retreatment after the first relapse. Lenalidomide-based regimens were predominant in the third and subsequent lines of therapy. Depth of response decreased with each treatment line, with half of patients achieving at least very good partial response (&gt;= VGPR) in the first line, while only one-fourth achieved &gt;= VGPR in the third or subsequent lines. Time to progression was longer in patients with better response levels. CONCLUSIONS: Inadequate access to advanced antimyeloma regimens and-in some countries-stem cell transplantation highlights the challenges of MM treatment in the region. Information on real-world patient management and its outcomes can provide valuable input for decision makers to effectively allocate limited resources.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Polskie Archiwum Medycyny Wewnetrznej

ISSN

0032-3772

e-ISSN

—

Svazek periodika

128

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

PL - Polská republika

Počet stran výsledku

12

Strana od-do

500-511

Kód UT WoS článku

000448876300003

EID výsledku v databázi Scopus

2-s2.0-85054338703